Immune checkpoint inhibitor (ICI) treatments benefit some patients with metastatic cancers, but predictive biomarkers are needed. Findings in selected cancer types suggest that tumor mutational burden (TMB) may predict clinical response to ICI. To examine this association more broadly, we analyzed the clinical and genomic data of 1,662 advanced cancer patients treated with ICI, and 5,371 non-ICI-treated patients, whose tumors underwent targeted next-generation sequencing (MSK-IMPACT). Among all patients, higher somatic TMB (highest 20% in each histology) was associated with better overall survival. For most cancer histologies, an association between higher TMB and improved survival was observed. The TMB cutpoints associated with improved survival varied markedly between cancer types. These data indicate that TMB is associated with improved survival in patients receiving ICI across a wide variety of cancer types, but that there may not be one universal definition of high TMB.
In recent years, ICI therapy has revolutionized the treatment of patients with advanced-stage cancers. These agents include antibodies that target CTLA-4 or PD-1/PD-L1 1 . Durable benefit, however, is limited to a minority of patients. Recently, several large phase 3 trials have reported negative results in both unselected patients and selected groups, highlighting the clinical need to identify better predictive biomarkers [2] [3] [4] [5] . Early reports have suggested that PD-L1 immunohistochemistry, T-cell infiltration levels, T-cell receptor clonality, gene expression signatures and peripheral blood markers may correlate with clinical response 6 . Additionally, an association between high mutational load and clinical benefit was observed in small cohorts of patients with melanoma treated with CTLA-4 blockade 7, 8 , and non-small cell lung cancer (NSCLC), patients with melanoma and bladder cancer treated with PD-1/PD-L1 inhibitors [9] [10] [11] . However, it is unclear whether TMB is robustly predictive of clinical benefit across diverse human cancers, or outside of these specific clinical trial populations.
In previous studies, mutation load was determined by using whole-exome sequencing, which is not widely utilized in routine clinical care. Currently, the majority of precision oncology platforms use next-generation sequencing of targeted gene panels. At Memorial Sloan Kettering Cancer Center (MSK), as part of clinical care, patients undergo genomic profiling with the Food & Drug Administration (FDA)-authorized Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) assay 12 . This test is performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory environment and identifies somatic exonic mutations in a predefined subset of 468 cancer-related genes (earlier versions included 341 or 410 genes), by using both tumorderived and matched germline normal DNA.
We examined the association between nonsynonymous somatic TMB, as measured by MSK-IMPACT, and overall survival after treatment with ICI. The cohort included 1,662 patients whose Tumor mutational load predicts survival after immunotherapy across multiple cancer types tumors were profiled by next-generation sequencing and who had received at least one dose of ICI therapy, representing a variety of cancer types with a sufficient number of patients for analysis ( Supplementary Fig. 1 ). Patients who had received atezolizumab, avelumab, durvalumab, ipilimumab, nivolumab, pembrolizumab or tremelimumab as monotherapy or in combination were included in the study. Most patients (1, 446 , representing 94% of tumors excluding glioma) had stage IV or metastatic disease. A small number of patients had locoregionally recurrent disease (n = 10) or were melanoma patients with regionally advanced unresectable disease (stage III, n = 989 (Supplementary Table 1 ). In total, 146 received anti-CTLA-4, 1,256 received anti-PD-1 or PD-L1, and 260 received a combination of anti-CTLA-4 and anti-PD-1/PD-L1 therapies. A large number of patients had cancers for which ICI is FDA-approved, including 350 NSCLCs, 321 melanomas, 151 renal cell carcinomas, 214 bladder cancers and 138 head and neck squamous cell cancers (Supplementary Table 2 ). To calculate TMB, the total number of somatic nonsynonymous mutations was normalized to the total number of megabases sequenced. Overall survival was measured from the date of first ICI treatment to time of death or most recent follow-up. The median follow-up was 19 months (range 0-80, with 830 (50%) patients alive and censored at most recent follow-up).
We defined TMB subgroups by percentile within each histology. We took this approach because the median and range of mutational load have been shown to vary across tumor types 13 ; therefore, a universal cutoff for 'high TMB' would be enriched for tumor types with higher mutation load. Across the entire cohort, stratifying tumors by TMB decile within histology showed that a higher number of mutations was associated with improved overall survival. This significant association, stratified by histology, was seen across a variety of cutpoints chosen to define the high-TMB group (ranging from the top 10-50%; Fig. 1a and Supplementary Figs. 3 and 4) . A clear trend toward decreasing hazard ratio (HR) of death with increasing TMB cutoff was observed across cancer types, demonstrating increasing benefit from ICI with higher TMB (Fig. 1b and Supplementary Fig. 3 ) 14 .
To confirm that these results were present across multiple cancer types, we performed two additional analyses. First, a multivariable analysis across the entire cohort using Cox proportional-hazards regression demonstrated that the tumor mutation burden was significantly associated with overall survival both as a continuous variable (HR = 0.985, P = 3.4 × 10 ) and with a binary cutoff (top 20% of each histology, HR = 0.61, P = 1.3 × 10 −7 ), with adjustment for cancer type, age, drug class of ICI and year of ICI start (Table 1) . Furthermore, this association remained significant with removal of melanoma and NSCLC patients from the cohort (Supplementary Table 2 ), thus indicating that this effect was not solely driven by these histologies.
We also performed a stratified analysis within each cancer type by selecting the highest mutation load quintile (top 20%) in each histology as the TMB-high group. Using this approach, we observed a similar association of longer overall survival with higher TMB (top 20% within each histology) across multiple cancer types ( Fig. 2 and Supplementary Fig. 5 ). Although the effect for some individual cancers did not reach statistical significance, possibly because of smaller sample size, the numerical trend of better overall survival (HR < 1) was observed in nearly all cancer types, with glioma the clearest exception. Together, these data indicate that the association between TMB and improved survival after ICI is likely to be present in most cancer histologies.
Consistent with varying distributions of TMB across histologies, the TMB cutoff associated with the top 20% of each cancer type varied markedly (Fig. 2) . Importantly, this result suggests that there is not likely to be a universal number defining high TMB that is predictive of clinical benefit to ICI across all cancer types, and that the optimal cutpoint is likely to vary for different cancers.
A similar numerical trend was observed for longer overall survival with TMB measured as a continuous variable across many Cox proportional hazards multivariable analysis of overall survival in 1,662 patients treated with immune checkpoint inhibitor (ICI) demonstrating the hazard ratios for individual covariates.
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histologies, concordant with the number of patients in the subgroup ( Supplementary Fig. 6 ). In agreement with differences in overall survival, we also observed similar associations between TMB and rates of objective response/clinical benefit to ICI, or progressionfree survival, in patients with cancer types for which response data were available-NSCLC, melanoma, esophagogastric, head and neck, and renal cell cancer [15] [16] [17] ( Supplementary Figs. 7 and 8 ). To investigate the possibility that the observed survival differences among patients with higher-TMB tumors might simply be attributable to a general prognostic benefit of high mutational load, unrelated to ICI, we analyzed the outcomes of 5,371 patients with metastatic cancers who did not receive ICI and whose tumors were sequenced with MSK-IMPACT. In these patients, there was no association between higher TMB and improved overall survival (HR = 1.12, P = 0.11). This lack of prognostic benefit was also observed within each histology ( Supplementary Figs. 5 and 9 ).
Of note, the TMB cutpoint for the top 20% of colorectal cancer patients was high (52.2/Mb), potentially consistent with many MSIhigh colorectal tumors receiving ICI treatment. To evaluate the possibility that the ICI-treated cohort of patients might be enriched for those with higher TMB (if, for example, clinicians were more likely to triage higher-TMB patients to ICI therapy), we repeated the survival analyses, instead calculating the top 20% of TMB among all (both ICI-and non-ICI-treated) patients. The TMB cutpoints in other cancer types were not changed with this calculation, and the associations with survival in each cancer type remained very similar in both the ICI-and non-ICI-treated cohorts ( Supplementary  Figs. 10 and 11) .
Distinctly from the other cancer types, there was no association between higher TMB and improved survival in patients with glioma; in fact, the trend was toward poorer survival. Although there have been case reports of dramatic responses to ICI in patients with glioblastoma associated with childhood biallelic mismatch repair deficiency 18 , mismatch repair is very rare in glioblastoma, and higher TMB in many glioma patients may reflect previous exposure to the alkylating agent temozolomide, which can promote the expansion of less immunogenic subclonal mutations 19 . Alternatively, antitumor immune responses in the central nervous system may be distinct and less dependent on TMB.
As would be expected in a large multicancer analysis of tumors sequenced as part of clinical care, the patients included were heterogeneous: some had been heavily pretreated, whereas others were treated with a variety of combination therapies. The timing of MSK-IMPACT testing relative to ICI start was also variable. Nevertheless, the finding of a significant association with overall survival in a heterogeneous cohort underscores the robustness of TMB as a predictive biomarker, thus suggesting that it is likely to be clinically meaningful. TMB, as measured by targeted NGS panels such as MSK-IMPACT, has previously been shown to have a high correlation with total mutational burden, as measured by whole-exome sequencing [20] [21] [22] [23] [24] . MSK-IMPACT offers the advantage of matched normal germline sequencing for each patient, permitting precise identification of true somatic mutations.
Although TMB measured in exome sequencing is highly correlated with measurements in targeted sequencing, it is important to note that numerical cutpoints may differ across platforms. Additionally, we note that TMB cutoffs for individual histologies may not represent the ideal values for clinical use, and they are shown primarily to demonstrate that a relationship exists between TMB and survival for each histology. We chose a top-twentieth percentile cutoff for TMB to dichotomize our data, but this does not imply any clinical significance to this threshold.
The variable threshold of TMB across histologies can probably be attributed to distinct tumor microenvironments as well as the numerous other factors shown to independently predict response to ICI, including clonality, immune infiltration, immune cell exclusion, human leukocyte antigen genotype and alterations and expression levels of checkpoint molecules, as well as others 19, [25] [26] [27] [28] . Our data overall suggest that TMB is associated with increasing overall survival in a dose-dependent fashion. The pancancer nature of this biomarker probably reflects fundamental mechanisms by which 
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NATure GeNeTICS ICI functions. Our data are also consistent with the hypothesis that higher mutation load is associated with a higher number of tumor neoantigens presented on major histocompatibility complex molecules that facilitate immune recognition as foreign and the development of an antitumor immune response 29, 30 . This finding is in line with the observation that patients with hypermutated tumors as a result of defective mismatch repair have high response rates to pembrolizumab, a finding that had led to the FDA's tissue/site-agnostic approval of this agent for microsatellite-instability-high or mismatch-repair-deficient tumors 31 . Further elucidation of appropriate mutational-load cutoffs with integration of relevant clinical variables within each cancer type will be necessary, probably in the context of prospective clinical studies, to allow for implementation of TMB as a predictive biomarker.
Our study addresses several fundamentally important questions in immuno-oncology. Mutational load can predict survival across diverse types of human cancers and is relevant in patients treated with either anti-CTLA-4 or anti-PD-1 therapies. Second, previous studies on the association between mutational load and survival after ICI had examined small cohorts, and therefore the effects of TMB on clinical benefit could not be quantified in a precise manner. This study presents genomic data from the largest cohort of patients treated with ICI to date and demonstrates the continuous association between higher TMB and superior overall survival. Capturing as little as 3% of the coding exome by using targeted panels such as MSK-IMPACT appears to provide a sufficient estimation of total tumor mutational load conferring predictive value for patients in whom ICI treatment is being considered. Finally, the mutational number defining TMB -high appears to vary across cancer types, and there is unlikely to be a universal number that defines the likelihood of benefit from ICI across all histologies.
Given the potential toxicities of immunotherapy and the highly variable response to ICI, as well as the significant economic cost of these agents, there is an urgent need for biomarkers that can predict immunotherapy response. Future studies that integrate other genomic or pathologic biomarkers may allow for the development of an even more optimized predictive test to inform clinical decisions on the use of ICI.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/ s41588-018-0312-8.
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Methods
Patient selection. After receiving institutional review board (IRB) approval at MSK, institutional pharmacy records were used to identify patients who had received at least one dose of immunotherapy (atezolizumab, avelumab, durvalumab, ipilimumab, nivolumab, pembrolizumab or tremelimumab), and these were then cross-referenced with patients who had MSK-IMPACT testing done in the context of routine clinical care. Cancer types with more than 35 patients on initial collection were selected for further analysis in the cohort. Most patients who received MSK-IMPACT testing on tumor tissue are enrolled in an IRB-approved institutional research protocol (NCT01775072), with the remaining patients receiving testing as part of routine clinical care; all patients provided informed consent, permitting return of results from sequencing analyses and broader characterization of banked specimens for research. Details of tissue processing and next-generation sequencing and analysis were previously described 11 . Importantly, concurrent sequencing of germline DNA from peripheral blood was performed for all samples to identify somatic tumor mutations. Patients enrolled in ongoing clinical trials for which publication of outcomes data was prohibited were removed, as were a small proportion of patients with either localized disease treated in the neoadjuvant setting (n = 9) or localized disease. Other preceding or concurrent non-ICI treatments were not recorded or accounted for in the analysis. The timing of tissue pathology on which MSK-IMPACT was performed relative to ICI administration is also heterogenous, with a small portion of patients receiving testing after ICI administration.
Mutational-load assessment and statistical analysis. The total number of somatic mutations identified was normalized to the exonic coverage of the respective MSK-IMPACT panel in megabases. Mutations in driver oncogenes were not excluded from the analysis. Overall survival analysis on ICI patients was performed from the date of first infusion of any ICI. For patients who received multiple courses of ICI, the first treatment was used for analysis. Patients were censored at the date of most recently attended appointment at MSK if death was not recorded in the electronic medical record.
For analysis of patients who did not receive ICI, all patients for whom MSK-IMPACT data were available across all histologies were included. Overall survival analysis was performed from the date of first infusional chemotherapy.
Kaplan-Meier survival analysis was performed, and log-rank P values are reported. Multivariable analysis was performed with Cox proportional hazard regression with inclusion of variables significant on univariate regression, including normalized TMB, cancer type, age, ICI drug class and year of ICI administration. The year of ICI administration was included to avoid any possible differences in patients treated in the early years when MSK-IMPACT testing was available.
For each histology, we subsequently identified cases in the top twentieth percentile of TMB and determined the log-rank P value for difference in overall survival and the direction of the effect with a HR determined from a coxph model. Additional analyses were performed with the TMB cutoff ranging from 10% to 50%, as well as with the TMB cutoff instead defined among all patients (both ICIand non-ICI-treated patients).
Response data for individual histologies were obtained from published analyses of clinical outcome in the cohorts of patients with NSCLC or esophagogastric cancer patients 15, 16 . For patients with head and neck cancer, radiology records were reviewed manually to determine evidence of progression or tumor response. In these tumor types, clinical benefit was defined as any partial/complete response, or evidence of stable disease for ≥ 6 months. For renal cell carcinoma, time to next treatment was recorded manually for all patients. Statistical analysis was performed in R by using the survival package. Graph-Pad Prism was used for basic analysis and generating graphs.
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Data availability
Data necessary to reproduce the figures are provided in Supplementary Data. All data are publicly available at http://www.cbioportal.org/study?id= tmb_mskcc_2018. The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Software and code
Policy information about availability of computer code
Data collection
No custom code or software was used for data collection.
Data analysis
Analysis was performed in Graphpad Prism (7.0) as well as R (3.3.2) using survival and coxph package.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability
All data is publicly available at http://www.cbioportal.org/study?id=tmb_mskcc_2018 nature research | reporting summary
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Field-specific reporting Please select the best fit for your research. If you are not sure, read the appropriate sections before making your selection. All studies must disclose on these points even when the disclosure is negative.
Sample size
Sample size was determined based on the the number of patients available retrospectively that met the inclusion criteria.
Data exclusions Patients with resectable localized disease were excluded from analysis as initially planned. Patients with certain histologies for which active studies were being performed and had not been published yet were excluded due to data embargo.
Replication
Data was replicated with several different analytic approaches as well as with training/validation analysis with concordant results.
Randomization No randomization was performed as this was a retrospective study.
Blinding
Blinding was not possible for the analysis as it was done retrospectively and there was no subjective analysis that was performed that could be biased by knowledge.
Reporting for specific materials, systems and methods 
Human research participants
Policy information about studies involving human research participants
Population characteristics
Analysis was performed on patients who had targeted next generation sequencing under a clinical research protocol at MSKCC. Metastatic patients across a broad range of histologies and age ranges were selected based on whether they received the indicated treatments. Covariate characteristics are summarized in Supp Table 1 
Recruitment
This study was done retrospectively and no patients were directly recruited.
